Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin AnalogTip Ranks·10 hours ago01276+1.20%6002760.00%
Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billionPUBT·15 hours ago02196+0.79%00656+1.13%
From confidence to capital: Positioning biotech for the next growth cyclebiopharmadive·2 days ago, 10:38 AMLABU-4.04%LABD+3.70%
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit ForecastsAASTOCKS News·2 days ago, 10:29 PM01276+1.20%6002760.00%
Chinese biotech overtakes AI as emerging-market growth tradeBusinesstimes News·2 days ago, 10:14 PM300765+0.84%AZN+0.48%
As weight-loss drug orders surge, global funds pile into China’s WuXi AppTecSCMP·Jul 24 at 05:39 AM02359+0.25%603259-0.47%
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line UseTip Ranks·Jul 23 at 07:37 AM01276+1.20%6002760.00%
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatmentPUBT·Jul 23 at 07:32 AM01276+1.20%6002760.00%
WuXi AppTec joins FTSE4Good Index Series for fourth straight yearPUBT·Jul 21 at 06:54 PM02359+0.25%603259-0.47%
China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global TotalAASTOCKS News·Jul 20 at 01:00 AM513060+0.19%1598590.00%
China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New HighAASTOCKS News·Jul 20 at 01:00 AM510660+8.00%159992-0.35%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Receives a Buy from Morgan StanleyTip Ranks·Jul 17 at 07:27 PM01276+1.20%6002760.00%
IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanomaPUBT·Jul 17 at 08:00 AMIDYA-1.58%01276+1.20%
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs | IDYA Stock NewsStockTitan·Jul 17 at 12:00 AMIDYA-1.58%6002760.00%
CLSA Sticks to Its Buy Rating for WuXi AppTec Co., Ltd. Class H (2359)Tip Ranks·Jul 16 at 07:26 PM02359+0.25%603259-0.47%
